RU2019132475A - Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1, для лечения амилоидоза al - Google Patents
Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1, для лечения амилоидоза al Download PDFInfo
- Publication number
- RU2019132475A RU2019132475A RU2019132475A RU2019132475A RU2019132475A RU 2019132475 A RU2019132475 A RU 2019132475A RU 2019132475 A RU2019132475 A RU 2019132475A RU 2019132475 A RU2019132475 A RU 2019132475A RU 2019132475 A RU2019132475 A RU 2019132475A
- Authority
- RU
- Russia
- Prior art keywords
- antigen receptor
- signaling domain
- amino acid
- chimeric antigen
- acid sequence
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims 6
- 208000023761 AL amyloidosis Diseases 0.000 title claims 2
- 102000006306 Antigen Receptors Human genes 0.000 title 1
- 108010083359 Antigen Receptors Proteins 0.000 title 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 title 1
- 238000000034 method Methods 0.000 claims 14
- 230000011664 signaling Effects 0.000 claims 14
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 125000006850 spacer group Chemical group 0.000 claims 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 6
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 2
- 102100033467 L-selectin Human genes 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (14)
1. Способ лечения амилоидоза легкой цепи, включающий введение пациенту, нуждающемуся в этом, популяции человеческих Т-клеток, трансдуцированных вектором, содержащим кассету экспрессии, кодирующую химерный рецептор антигена, где химерный рецептор антигена содержит: scFv против CS1; спейсерную область; трансмембранный домен; домен косигнализации и домен сигнализации CD3ζ.
2. Способ по п. 1, в котором химерный рецептор антигена содержит: scFv против CS1; спейсерную область; трансмембранный домен CD28; домен косигнализации CD28 и домен сигнализации CD3ζ.
3. Способ по п. 1, в котором химерный рецептор антигена содержит: scFv против CS1; спейсерную область; трансмембранный домен CD4; домен косигнализации 4-1 ВВ и домен сигнализации CD3ζ.
4. Способ по п. 1, в котором химерный рецептор антигена содержит: scFv против CS1; спейсерную область, содержащую аминокислотную последовательность, выбранную из SEQ ID NO: 2-5 и 9-12; трансмембранный домен CD4; домен косигнализации 4-1 ВВ и домен сигнализации CD3ζ.
5. Способ по п. 1, в котором химерный рецептор антигена содержит: scFv против CS1; спейсерную область, содержащую аминокислотную последовательность, выбранную из SEQ ID NO: 2-5 и 9-12; трансмембранный домен CD28; домен косигнализации CD28 и домен сигнализации CD3ζ.
6. Способ по п. 1, в котором химерный рецептор антигена содержит: scFv против CS1; спейсерную область, содержащую аминокислотную последовательность, выбранную из SEQ ID NO: 2-5 и 9-12; трансмембранный домен CD4; домен косигнализации 4-1 ВВ и домен сигнализации CD3ζ.
7. Способ по п. 1, в котором химерный рецептор антигена содержит: спейсерную область, содержащую аминокислотную последовательность, выбранную из SEQ ID NO: 2-5 и 9-12; трансмембранный домен CD28; домен косигнализации CD28 и домен сигнализации CD3ζ.
8. Способ по п. 1, в котором химерный рецептор антигена содержит аминокислотную последовательность, по меньшей мере на 95% идентичную аминокислотной последовательности, выбранной из SEQ ID NO: 30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 44 и 45.
9. Способ по п. 1, в котором химерный рецептор антигена содержит аминокислотную последовательность, идентичную аминокислотной последовательности, выбранной из SEQ ID NO: 30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 44 и 45.
10. Способ по п. 1, в котором химерный рецептор антигена содержит аминокислотную последовательность, идентичную аминокислотной последовательности, выбранной из SEQ ID NO: 30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 44 и 45, причем каждая имеет не более 5 замен одиночных аминокислот.
11. Способ по п. 1, в котором по меньшей мере 20%, 30% или 40% трансдуцированных человеческих Т-клеток представляют собой центральные Т-клетки памяти.
12. Способ по п. 1, в котором по меньшей мере 30% трансдуцированных человеческих Т-клеток представляют собой CD4+ и CD62L+ или CD8+ и CD62L+.
13. Способ по п. 1, в котором популяция человеческих Т-клеток является аутологичной по отношению к данному пациенту.
14. Способ по п. 1, в котором популяция человеческих Т-клеток является аллогенной по отношению к данному пациенту.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473980P | 2017-03-20 | 2017-03-20 | |
| US62/473,980 | 2017-03-20 | ||
| PCT/US2018/023381 WO2018175453A1 (en) | 2017-03-20 | 2018-03-20 | Cs1 targeted chimeric antigen receptor-modified t cells for treatment of al amyloidosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022116943A Division RU2022116943A (ru) | 2017-03-20 | 2018-03-20 | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1, для лечения амилоидоза al |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019132475A true RU2019132475A (ru) | 2021-04-21 |
| RU2019132475A3 RU2019132475A3 (ru) | 2021-07-29 |
| RU2774895C2 RU2774895C2 (ru) | 2022-06-27 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019132475A3 (ru) | 2021-07-29 |
| US20200188432A1 (en) | 2020-06-18 |
| CN110636849A (zh) | 2019-12-31 |
| BR112019019606A2 (pt) | 2020-04-14 |
| KR20190131061A (ko) | 2019-11-25 |
| MX2019011225A (es) | 2020-01-21 |
| AU2018240111A1 (en) | 2019-10-10 |
| WO2018175453A1 (en) | 2018-09-27 |
| EP3600352A1 (en) | 2020-02-05 |
| CA3057452A1 (en) | 2018-09-27 |
| JP2020511498A (ja) | 2020-04-16 |
| US11744862B2 (en) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| IL292650B2 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| Elinav et al. | Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor | |
| ES2800906T3 (es) | Métodos mejorados para producir terapias celulares adoptivas | |
| Krug et al. | Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone | |
| RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| RU2015153250A (ru) | Cd19-специфический химерный антигенный рецептор и его применения | |
| WO2015123642A1 (en) | Chimeric antigen receptors and methods of making | |
| Koristka et al. | Flexible antigen-specific redirection of human regulatory T cells via a novel universal chimeric antigen receptor system | |
| RU2017132293A (ru) | Химерный белок | |
| JP2018524987A5 (ru) | ||
| JP2017522862A5 (ru) | ||
| RU2018140056A (ru) | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена | |
| Tal et al. | An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities | |
| Huang et al. | Molecular basis of the differentiation and function of virus specific follicular helper CD4+ T cells | |
| JP2020512284A5 (ru) | ||
| JP2018531016A5 (ru) | ||
| WO2019238016A1 (zh) | 一种嵌合单链分子及其应用 | |
| WO2021136415A1 (zh) | 一种纯化ucart细胞的方法与应用 | |
| RU2019132475A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1, для лечения амилоидоза al | |
| Douka et al. | Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy | |
| Bonavida et al. | Successes and challenges of NK immunotherapy: Breaking tolerance to cancer resistance | |
| RU2022116943A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1, для лечения амилоидоза al |